GRI Bio (GRI) to Release Quarterly Earnings on Thursday

GRI Bio (NASDAQ:GRI) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($6.80) per share for the quarter.

GRI Bio Stock Performance

GRI Bio stock opened at $8.06 on Tuesday. GRI Bio has a 52 week low of $5.12 and a 52 week high of $176.80. The firm has a market capitalization of $4.23 million, a price-to-earnings ratio of -0.70 and a beta of -2.10. The company has a 50 day moving average price of $8.79 and a 200 day moving average price of $10.62.

Analyst Ratings Changes

Several analysts have recently commented on GRI shares. HC Wainwright started coverage on GRI Bio in a research report on Monday, December 9th. They issued a “buy” rating and a $170.00 target price for the company. Ascendiant Capital Markets lifted their price objective on GRI Bio from $204.00 to $221.00 and gave the company a “buy” rating in a research report on Thursday, December 5th.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.